We simplify
market access for
medical devices

Our proven experts guide you through medical device
CE certification. You gain hands-on support in
regulatory affairs and quality management, ensuring
regulatory compliance. Plus, as a Swiss Authorised
Representative, we facilitate your access to the
medical device market in Switzerland.

One partner for your medical device compliance

Medical device regulatory consultant advising client on CE marking

Obtain CE mark with proven experts

Decomplix becomes your professional compliance partner. We guide you to your CE mark and ensure your compliant quality management. You get expert advice on how to overcome key regulatory hurdles on the way to getting your product to market.

More about our CE mark services

Beni Hirt, CEO of Decomplix, and Oliver Lammert collaborating on laptops in the Decomplix office

CE-certified medical device software

Transform your algorithm into a CE-certified medical device software in less than a year. Decomplix, with its partner platform Evidencio, can offer a fast, proven, de-risked solution.

More about our medical device software service

Two professionals in an in-depth discussion seated in lounge chairs in an office setting

Swiss Authorised Representative

As your Swiss Authorised Representative (CH-REP), we ensure your market access in Switzerland. Our high level of compliance and regulatory knowledge was confirmed with a Swissmedic inspection with no non-conformities in April 2022.

More about our CH-REP service

Two colleagues reviewing a document together at a standing desk in a modern office

Compliance for Swiss medical device importers

We offer consulting, training and ready-to-use templates for procedures, checklists and other tools for the compliant import of medical devices into Switzerland. Our proven experts tailor the processes together with you to your needs for fixed price.

More about our importers service

Overhead view of two professionals working together on a laptop at a round table

Swissmedic: Inspection of importers

In 2025, Swissmedic will inspect Swiss importers of medical devices for compliance with the MedDO and IvDO. Our experts will prepare you efficiently for the inspection so that you do not risk any interruption to your business.

More about our inspection readiness check

100+ medical device and in-vitro diagnostic companies of all shapes and sizes trust Decomplix — from startups to corporates, from Switzerland to all around the globe.

Read more about us
Illustration of various medical devices including a patient monitor, surgical tools, blood pressure cuff, and a smartphone
Nicolas Höfler
Nicolas HöflerGroupe Mutuel, Switzerland
«Decomplix gives us the necessary security in the use of software as a medical device during digitalization.»
Dr. Corina Matzdorf
Dr. Corina Matzdorfulrich GmbH & Co. KG, Germany
«Being a German high-quality manufacturer for medical devices with more than 110 years of experience and operating worldwide, we feel very safe with Decomplix.»
Renate Reiss
Renate ReissNeoNavia GmbH, Germany
«Due to service quality, regulatory knowledge, and reliability, we can highly recommend Decomplix as CH-REP.»
Manuel Baumann
Manuel BaumannOviva AG, Switzerland
«We benefited tremendously from Decomplix's experience and expertise in working with the Swiss authority, Swissmedic, and with Notified Bodies.»
Benjamin Schlenker
Benjamin SchlenkerCanvys – Visual Technology Solutions, Germany
«With Decomplix as our CH-REP and partner, we feel well-supported. The collaboration is exceptionally professional and efficient.»
Teija Ålander
Teija ÅlanderOrkla – Wound Care, Sweden
«We are very satisfied with the support and helpful knowledge of Decomplix as CH-REP.»
Susanne Vesterinen
Susanne VesterinenRFSU AB, Sweden
«It feels very good to have Decomplix as CH-REP.»
Florian Schulz
Florian SchulzOBERON GmbH Fiber Technologies, Germany
«Decomplix offers a professional approach and streamlined process for compliance and specific requirements of the Swiss market.»
Claudia Handler
Claudia HandlerCARE diagnostica, Austria
«We appreciate the clear procedure, the professional approach, and the uncomplicated cooperation and highly recommend Decomplix as a business partner.»
Jonas Widmer
Jonas WidmerBalgrist University Hospital, Switzerland
«With the regulatory evaluation of our planning software, we were able to take key steps in product development with Decomplix.»
Eric Tscharner
Eric TscharnerHASA OPTIX, Belgium
«As a premium manufacturer of ophthalmic instruments, we feel very secure with Decomplix.»
Dominik Gutzler
Dominik GutzlerCytoSorbents Europe GmbH, Germany
«Decomplix as CH-REP is our partner of choice, providing us with a great comprehensive service and allowing us to focus our internal resources on other projects.»
Sang-Il Kim
Sang-Il KimFederal Office of Public Health FOPH, Switzerland
«Decomplix has done an excellent job for the SwissCovid App while working under high pressure. The team is reliable, fast and extremely competent.»
Alain Kamm
Alain KammSanitas Health Insurance, Switzerland
«For our digital health initiatives, we feel we are in safe hands with Decomplix.»
Thomas Farner
Thomas FarnerAxon Lab AG, Switzerland
«Thanks to Decomplix' great expertise, pragmatic approach and support, we were ready for the CH requirements for IVD/MD importers and CH-REPs within a short time.»
Runa Emura
Runa EmuraKonan Medical Inc., Japan
«Decomplix quickly provides us with new and updated information on medical devices in Switzerland. We are very satisfied with their service.»
José Näf
José Näfnahtlos GmbH, Switzerland
«Decomplix' Regulatory Support helps us quick and uncomplicated — I can thoroughly recommend it to any medical start-up.»
Matías Hosiasson
Matías HosiassonBiomedical Devices SpA, Chile
«Decomplix took a pragmatic approach and enabled us to make an informed decision on the regulatory pathway.»
Hemera Beretta
Hemera BerettaNeuroPro AG, Switzerland
«Decomplix provided valuable expertise for understanding the regulatory framework of medical device, data protection and IT security.»
Pascal Reichmuth
Pascal ReichmuthRikai AG, Switzerland
«Thanks to the comprehensive strategy workshop with Decomplix, we understand how to classify and develop our product Rikai as medical device software.»
Markus Piller
Markus PillerMedid AG, Switzerland
«The flexibility, broad-based expertise and the will to always find a suitable solution for our problems as a small MedTech company are qualities we greatly appreciate about Decomplix.»

Regulatory Affairs News

23.10.2025.

European Commission

The last amendment to the official list of Harmonised Standards (i.e. Implementing Decision (EU) 2025/2078 of 17 October 2025) only introduced standards relative to surgical clothing and drapes, medical face masks, and  low temperature steam and formaldehyde sterilizers. It is however important to be aware that a new Consolidated List of HS under the EU MDR is now available.

Swissmedic

The information sheet for the cosmetic sector – Parenterals without an intended medical purpose is newly published, which provides guidance on some borderline topics. Although it is intended as a pharmaceutical/cosmetic borderline guideline, it covers injectables that can also be Annex XVI products and clarifies how such products qualify as regards enforcement and provides an overview and guidance for professionals, particularly those working in the cosmetic sector. 

03.10.2025.

Swissmedic

The swissdamed User Guide UDI Devices Module V.2 has been published, featuring the addition of Chapter 8, “Discard UDIs”:

  • Registered UDI-DIs may be discarded if they contain incorrect data that cannot be corrected via an update.
  • A reason must be provided when discarding the UDIs
  • The discarded UDIs will be listed in the “My UDIs” section

EU Commission

The EU Commission’s consultation process on the draft guidance and form for reporting serious incidents for high-risk AI systems under the AI Act is running until November 7th. The final guidance and form shall become applicable on August 2nd, 2026.

For medical devices and IVDs, this reporting would only apply to infringement of fundamental rights that significantly interfere with Charter-protected rights on a large scale, as all other serious incidents relative to AI-enabled medical device software would be routed through EU MDR/IVDR Vigilance.

26.09.2025.

MedTech Europe

MedTech Europe has published an internal guidance to its members on their participation in the European Commission’s public Call for Evidence concerning the targeted revision of the EU rules on medical devices and IVD. Key areas for feedback are as follows:

  • Reducing administrative burden
  • Enhancing predictability and cost-efficiency of NB processes
  • Making conformity assessment proportional (fast-track reviews for low-risk/well established technologies, accelerated/holistic pathways for special devices, etc.)
  • Enabling further digitalisation
  • Streamlining procedures, including governance
  • Benefiting from international cooperation (MDSAP, MRA with CH, etc.)
  • Better alignment with other relevant legislation (e.g., AIA, EHDS, GDPR, REACH, PLD, etc.)

An open letter to the EC Commissioner on the targeted review of medical device legislation was published, outlining different proposals of actions needed to provide short-term relief while laying the foundation for a fully functioning regulatory system:

  • The legislative reform should cover both EU MDR and IVDR.
  • NBs should be overseen by a single & accountable governance structure.
  • Urgent (short-term) relief measures are needed:
    • An implementing act for NB setting maximum assessment timelines, defining the scope of notified changes, removing duplication of vigilance review, enabling early dialogues with the MFR and mitigating the re-certification.
    • Regulatory pathways for orphan & paediatric devices and breakthrough innovations.
    • Postponement of re-certification until the end of the transitional periods (2028) to allow NBs to focus on new certifications.

Latest from our blog